



SUVEN Life Sciences

Communication to investors **June 2019**

14-Aug-19

2019-20 Q1 results



Risk statement

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.

FINANCIAL QUICK VIEW

Quarter 1 – June 2019



	Q1-FY20 to Q4-FY19	Q1-FY20 to Q1-FY19
Growth in Revenue	-21.42%	1.10%
Growth in PAT	-16.62%	47.38%
Growth in EBIDTA	-14.68%	40.21%
Growth Pre-R&D EBIDTA	-16.37%	28.89%
Increase in R&D costs	-26.68%	-18.06%




MAJOR PROFITABILITY RATIOS

	30 Jun 2019	31 Mar 2019	30 Jun 2018
PAT to Income	28.29%	26.47%	19.41%
EBIDTA to Income	46.06%	42.42%	33.21%
Cash Flow to Income	31.04%	28.60%	22.16%
Pre-R&D EBITDA to Income	52.55%	49.37%	41.22%
R&D to Income	6.49%	6.95%	8.00%



INCOME COMPARISON




14-Aug-19

2019-20 Q1 results



PROFIT COMPARISON




14-Aug-19

2019-20 Q1 results




EBIDTA COMPARISON



14-Aug-19

2019-20 Q1 results

R & D – EXPENDITURE




14-Aug-19

2019-20 Q1 results



PRE-R&D EBIDTA




14-Aug-19

2019-20 Q1 results



PRE-R&D CASHFLOW



14-Aug-19

2019-20 Q1 results



Financial Snapshot

All figures are in INR Million, other than ratios and EPS

	Stand Alone					Consolidated				
	Q1 FY20	Q4 FY19	QoQ growth	Q1 FY19	YoY growth	Q1 FY20	Q4 FY19	QoQ growth	Q1 FY19	YoY growth
Income	2,019.93	2,570.53	-21.42%	1,997.90	1.10%	2,019.93	2,570.53	-21.42%	1,997.90	1.10%
Pre-R&D EBITDA	1,061.41	1,269.17	-16.37%	823.47	28.89%	1,053.08	1,260.14	-16.43%	813.01	29.53%
Pre-R&D EBITDA Margin	52.55%	49.37%	-	41.22%	-	52.13%	49.02%	-	40.69%	-
EBITDA	930.39	1,090.48	-14.68%	663.59	40.21%	624.50	789.84	-20.93%	535.43	16.64%
EBITDA Margin	46.06%	42.42%	-	33.21%	-	30.92%	30.73%	-	26.80%	-
EBIT	874.55	1,036.54	-15.63%	607.81	43.88%	874.55	1,036.54	-15.63%	479.66	82.33%
EBIT Margin	43.30%	40.32%	-	30.42%	-	43.30%	40.32%	-	24.01%	-
Financing costs	13.08	15.75	-	10.68	-	16.87	15.78	-	10.70	-
Taxes	290.04	340.32	-	209.41	-	290.04	340.32	-	209.41	-
Taxes to Profit	33.67%	33.34%	-	35.07%	-	52.56%	47.26%	-	44.65%	-
Net Profit after tax	571.43	680.47	-16.02%	387.73	47.38%	261.75	379.80	-31.08%	259.55	0.85%
NP Margin	28.29%	26.47%	-	19.41%	-	12.96%	14.78%	-	12.99%	-
EPS (basic & diluted not annualized)	4.49	5.34	-	3.05	-	2.06	2.98	-	2.04	-
Paid up share capital One Rupee Share)	127.28	127.28	-	127.28	-	127.28	127.28	-	127.28	-
Depreciation	55.50	54.63	-	55.08	-	55.50	54.63	-	55.08	-
R&D expenses	131.01	178.69	-26.68%	159.89	-18.06%	428.57	470.30	-8.87%	277.58	54.40%

14-Aug-19

2019-20 Q1 results



News Updates

- SUVN-502 Phase 2A clinical trial, indicated for patients with moderate Alzheimer's undertaken in USA completed with the Last Patient Last Visit (LPLV) on May 23, 2019.
- The completed clinical trial had an enrollment of 564 patients against the target of 537 patients in the study.
- The outcome of SUVN-502 is expected by Sept/Oct 2019 after completion of statistical analysis of the data.
- Suven Life Sciences presented in AAIC 2019, held in Los Angeles in July 2019.



News Updates

- During the period Suven secures 10 product patents covering regions/countries – Europe, India, Israel, Japan, Macau, Mexico, New Zealand, Sri Lanka and USA.
- SUVN-G3031 Phase 2 clinical trial, indicated for Narcolepsy (with and without Cataplexy), initiated in USA with an estimated enrollment of minimum of 114 patients and maximum of 171 patients in the study.
- Suven Life Sciences submitted application to National Company Law Tribunal (NCLT) for Demerger of Suven into two companies, focused on Discovery Research and CRAMS operations. For more info on the scheme of demerger please follow the link: <http://suven.com/schemeofarrangement.aspx>